The following article is part of conference coverage from the 2019 American Psychiatric Association Annual Meeting (APA 2019) in San Francisco, CA. Psychiatry Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in psychiatry. Check back for the latest news from APA 2019.

 

SAN FRANCISCO — Valbenazine and tetrabenazine may represent promising options for the treatment of tardive dyskinesia in patients on long-term antipsychotic medications, according to a literature review presented at the American Psychiatric Association Annual Meeting, held May 18-22, 2019, in San Francisco, California.

Related Articles

For this literature review, investigators searched medical publishing databases including   Pubmed, PsycINFO, Cochrane Review, and Psychiatry Online, using the following keywords: risk factors, treatment, valbenazine, deutetrabenazine, dyskinesia, and pathophysiology. This literature review provides an overview of the history of tardive dyskinesia, describes the associated pathophysiology, summarizes management options, and lists risk factors for tardive dyskinesia (eg, female sex, older age, pre-existing movement disorders, the overall health of the individual, and the type and modes of delivery of antipsychotic therapies).

Valbenazine and deutetrabenazine, which have recently received U.S. Food and Drug Administration (FDA) approval for the treatment of tardive dyskinesia have had promising results compared with previously available treatments, which included vitamin B6, Ginkgo biloba, branched-chain amino acids, ondansetron, benzodiazepines, and beta blockers.

“Tardive dyskinesia is a disabling, long term side effect of antipsychotic use. Many risks factors predispose patients to the development of symptoms. Until recently, there were no FDA-approved treatments. The newly approved medications valbenazine and tetrabenazine have shown promising results for the treatment of tardive dyskinesia,” concluded the review authors.

For more coverage of APA 2019, click here.

Reference

Spatcher M, Madhusoodanan S. Tardive dyskinesia: risk factors, prevention, and treatment. Poster presented at: American Psychiatric Association Annual Meeting; May 18-22, 2019; San Francisco, CA. Abstract 13.

This article originally appeared on Psychiatry Advisor